{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:49:19Z","timestamp":1790113759968,"version":"4.0.1"},"reference-count":220,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.cellsig.2020.109721","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T11:45:47Z","timestamp":1595418347000},"page":"109721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":134,"special_numbering":"C","title":["Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19"],"prefix":"10.1016","volume":"74","author":[{"given":"Ramarao","family":"Poduri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7812-2871","authenticated-orcid":false,"given":"Gaurav","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-3929","authenticated-orcid":false,"given":"Gowraganahalli","family":"Jagadeesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0005","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.antiviral.2013.08.015","article-title":"From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses","volume":"100","author":"Hilgenfeld","year":"2013","journal-title":"Antivir. Res."},{"issue":"19","key":"10.1016\/j.cellsig.2020.109721_bb0010","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/1743-422X-10-359","article-title":"In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East Respiratory Syndrome (MERS) Coronavirus infection","volume":"10","author":"Eckerle","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.cellsig.2020.109721_bb0020","series-title":"Coronavirus Disease 2019 (COVID-19): Situation Report, 92","author":"World Health","year":"2020"},{"issue":"4","key":"10.1016\/j.cellsig.2020.109721_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.013","article-title":"SnapShot: COVID-19","volume":"181","author":"Oberfeld","year":"2020","journal-title":"Cell"},{"issue":"10223","key":"10.1016\/j.cellsig.2020.109721_bb0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cellsig.2020.109721_bb0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1473-3099(20)30086-4","article-title":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study","volume":"20","author":"Shi","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.cellsig.2020.109721_bb0040","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci. China Life Sci."},{"issue":"5","key":"10.1016\/j.cellsig.2020.109721_bb0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25766","article-title":"Coronavirus disease 2019: what we know?","author":"He","year":"2020","journal-title":"J. Med. Virol."},{"issue":"Pt A","key":"10.1016\/j.cellsig.2020.109721_bb0055","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.phrs.2016.09.040","article-title":"Prevalence and prevention of cardiovascular disease and diabetes mellitus","volume":"113","author":"Balakumar","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"6489","key":"10.1016\/j.cellsig.2020.109721_bb0060","first-page":"356","article-title":"A rampage through the body","volume":"368","author":"Wadman","year":"2020"},{"issue":"3","key":"10.1016\/j.cellsig.2020.109721_bb0065","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cellsig.2020.109721_bb0070","series-title":"Coronaviruses: An Overview of their Replication and Pathogenesis, Coronaviruses","first-page":"1","author":"Fehr","year":"2015"},{"issue":"2","key":"10.1016\/j.cellsig.2020.109721_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2020.109721_bb0080","article-title":"COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles\u2019 heel conserved region to minimize probability of escape mutations and drug resistance","volume":"103749","author":"Robson","year":"2020","journal-title":"Comput. Biol. Med."},{"issue":"8","key":"10.1016\/j.cellsig.2020.109721_bb0085","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/656315","article-title":"The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes","volume":"202","author":"Liu","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cellsig.2020.109721_bb0090","series-title":"COVID-19 Docking Server: An Interactive Server for Docking Small Molecules, Peptides and Antibodies Against Potential Targets of COVID-19","author":"Kong","year":"2020"},{"key":"10.1016\/j.cellsig.2020.109721_bb0095","first-page":"1","article-title":"SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells","author":"Mu","year":"2020","journal-title":"Sci. China Life Sci."},{"issue":"26","key":"10.1016\/j.cellsig.2020.109721_bb0100","doi-asserted-by":"crossref","first-page":"9065","DOI":"10.1073\/pnas.0800502105","article-title":"Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution","volume":"105","author":"Zeng","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cellsig.2020.109721_bb0105","article-title":"Coronavirus hemagglutinin-esterase and spike proteins co-evolve for functional balance and optimal virion avidity","author":"Lang","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cellsig.2020.109721_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwaa036","article-title":"On the origin and continuing evolution of SARS-CoV-2","author":"Tang","year":"2020","journal-title":"Nat. Sci. Rev."},{"issue":"23","key":"10.1016\/j.cellsig.2020.109721_bb0115","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","article-title":"Nextstrain: real-time tracking of pathogen evolution","volume":"34","author":"Hadfield","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.cellsig.2020.109721_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25902","article-title":"Distinct viral clades of SARS-CoV-2: implications for modeling of viral spread","author":"Brufsky","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0125","article-title":"Analysis of codon usage and evolutionary rates of the 2019-nCoV genes","author":"Dilucca","year":"2020","journal-title":"bioRxiv"},{"issue":"7807","key":"10.1016\/j.cellsig.2020.109721_bb0130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2020.109721_bb0135","article-title":"Genotype and phenotype of COVID-19: their roles in pathogenesis","author":"Mousavizadeh","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"5","key":"10.1016\/j.cellsig.2020.109721_bb0140","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/pro.3873","article-title":"Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2","author":"Kim","year":"2020","journal-title":"Protein Sci."},{"issue":"4","key":"10.1016\/j.cellsig.2020.109721_bb0150","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"issue":"7798","key":"10.1016\/j.cellsig.2020.109721_bb0155","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cellsig.2020.109721_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.cellsig.2020.109721_bb0165","first-page":"30151","article-title":"The pivotal link between ACE2 deficiency and SARS-CoV-2 infection","volume":"S0953-6205","author":"Verdecchia","year":"2020","journal-title":"Eur. J. Intern. Med."},{"issue":"14","key":"10.1016\/j.cellsig.2020.109721_bb0170","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1073\/pnas.0809524106","article-title":"Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites","volume":"106","author":"Belouzard","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"42","key":"10.1016\/j.cellsig.2020.109721_bb0175","doi-asserted-by":"crossref","first-page":"15214","DOI":"10.1073\/pnas.1407087111","article-title":"Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein","volume":"111","author":"Millet","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.cellsig.2020.109721_bb0180","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/JVI.00128-13","article-title":"The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies","volume":"87","author":"Gierer","year":"2013","journal-title":"J. Virol."},{"issue":"43","key":"10.1016\/j.cellsig.2020.109721_bb0185","doi-asserted-by":"crossref","first-page":"12262","DOI":"10.1073\/pnas.1608147113","article-title":"Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism","volume":"113","author":"Park","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0190","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.cellsig.2020.109721_bb0195","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2014a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0200","doi-asserted-by":"crossref","first-page":"104742","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.cellsig.2020.109721_bb0205","article-title":"Structural basis for the recognition of the 2019-nCoV by human ACE2","author":"Yan","year":"2020","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/j.cellsig.2020.109721_bb0210","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/v12050497","article-title":"The SARS-CoV-2 exerts a distinctive strategy for interacting with the ACE2 human receptor","volume":"12","author":"Brielle","year":"2020","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.cellsig.2020.109721_bb0215","doi-asserted-by":"crossref","first-page":"e105114","DOI":"10.15252\/embj.20105114","article-title":"SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells","volume":"39","author":"Lukassen","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.cellsig.2020.109721_bb0220","article-title":"Structural basis of SARS-CoV-2 spike protein priming by TMPRSS2","author":"Hussain","year":"2020","journal-title":"bioRxiv"},{"issue":"10","key":"10.1016\/j.cellsig.2020.109721_bb0225","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.tim.2004.08.008","article-title":"Cellular entry of the SARS coronavirus","volume":"12","author":"Hofmann","year":"2004","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0230","article-title":"Repurposed single inhibitor for serine protease and spike glycoproteins of SAR-CoV-2","author":"Khadim Sheikh","year":"2020","journal-title":"ChemRxiv"},{"issue":"6965","key":"10.1016\/j.cellsig.2020.109721_bb0235","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2020.109721_bb0240","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.57309","article-title":"SARS-CoV-2 (COVID-19) by the numbers","volume":"9","author":"Bar-On","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.cellsig.2020.109721_bb0245","series-title":"The protein expression profile of ACE2 in human tissues, bioRxiv","author":"Hikmet","year":"2020"},{"key":"10.1016\/j.cellsig.2020.109721_bb0250","article-title":"Knowledge synthesis from 100 million biomedical documents augments the deep expression profiling of coronavirus receptors","author":"Venkatakrishnan","year":"2020","journal-title":"arXiv"},{"issue":"20","key":"10.1016\/j.cellsig.2020.109721_bb0255","article-title":"Elevated troponin in patients with Coronavirus Disease 2019 (COVID-19): possible mechanisms","volume":"S1071-9164","author":"Tersalvi","year":"2020","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.cellsig.2020.109721_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmii.2020.04.015","article-title":"ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome","author":"Devaux","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"6","key":"10.1016\/j.cellsig.2020.109721_bb0265","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/jmv.25722","article-title":"Understanding of COVID-19 based on current evidence","volume":"92","author":"Sun","year":"2020","journal-title":"J. Med. Virol."},{"issue":"5","key":"10.1016\/j.cellsig.2020.109721_bb0270","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme\u2013related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0275","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/HYPERTENSIONAHA.109.138420","article-title":"Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II\u2013dependent hypertension","volume":"55","author":"Wysocki","year":"2010","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.cellsig.2020.109721_bb0280","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1042\/CS20200163","article-title":"Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?","volume":"134","author":"Batlle","year":"2020","journal-title":"Clin. Sci. (Lond.)"},{"issue":"5","key":"10.1016\/j.cellsig.2020.109721_bb0285","doi-asserted-by":"crossref","first-page":"H1084","DOI":"10.1152\/ajpheart.00217.2020","article-title":"COVID-19, ACE2, and the cardiovascular consequences","volume":"318","author":"South","year":"2020","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"10","key":"10.1016\/j.cellsig.2020.109721_bb0290","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.cellsig.2020.109721_bb0295","first-page":"e924700","article-title":"An evidence based perspective on mRNA-SARS-CoV-2 vaccine development","volume":"26","author":"Wang","year":"2020","journal-title":"Med. Sci. Monit."},{"issue":"10","key":"10.1016\/j.cellsig.2020.109721_bb0300","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.cellsig.2014.06.011","article-title":"A century old renin\u2013angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology","volume":"26","author":"Balakumar","year":"2014","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0305","first-page":"L84","article-title":"Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia","volume":"297","author":"Jia","year":"2009","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-12074-3","article-title":"Ang-(1-7) is an endogenous \u03b2-arrestin-biased agonist of the AT 1 receptor with protective action in cardiac hypertrophy","volume":"7","author":"Teixeira","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.cellsig.2020.109721_bb0315","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1161\/HYPERTENSIONAHA.116.08118","article-title":"Cardioprotective angiotensin-(1\u20137) peptide acts as a natural-biased ligand at the angiotensin II type 1 receptor","volume":"68","author":"Galandrin","year":"2016","journal-title":"Hypertension"},{"issue":"Pt A","key":"10.1016\/j.cellsig.2020.109721_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.07.003","article-title":"Renin-angiotensin-aldosterone: an inclusive, an invigorative, an interactive and an interminable system","volume":"125","author":"Balakumar","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cellsig.2020.109721_bb0325","series-title":"Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study, Hypertension","author":"Yang","year":"2020"},{"issue":"2","key":"10.1016\/j.cellsig.2020.109721_bb0330","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/1470320314542829","article-title":"ACE2 activity was increased in atherosclerotic plaque by losartan: possible relation to anti-atherosclerosis","volume":"16","author":"Zhang","year":"2015","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"issue":"4","key":"10.1016\/j.cellsig.2020.109721_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.011","article-title":"The architecture of SARS-CoV-2 transcriptome","volume":"181","author":"Kim","year":"2020","journal-title":"Cell"},{"issue":"10224","key":"10.1016\/j.cellsig.2020.109721_bb0340","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0345","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virusres.2006.01.017","article-title":"Nidovirales: evolving the largest RNA virus genome","volume":"117","author":"Gorbalenya","year":"2006","journal-title":"Virus Res."},{"key":"10.1016\/j.cellsig.2020.109721_bb0350","article-title":"Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites","volume":"104793","author":"Shannon","year":"2020","journal-title":"Antivir. Res."},{"issue":"6492","key":"10.1016\/j.cellsig.2020.109721_bb0355","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2020.109721_bb0360","series-title":"SARS-Coronavirus-2 nsp13 Possesses NTPase and RNA Helicase Activities","author":"Shu","year":"2020"},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0365","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20192825","article-title":"Interplay of mRNA capping and transcription machineries","volume":"40","author":"Kachaev","year":"2020","journal-title":"Biosci. Rep."},{"issue":"5","key":"10.1016\/j.cellsig.2020.109721_bb0370","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3390\/cells9051267","article-title":"A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping","volume":"9","author":"Romano","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.cellsig.2020.109721_bb0375","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.dsx.2020.04.020","article-title":"Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response","volume":"14","author":"Astuti","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.cellsig.2020.109721_bb0380","series-title":"Structure of RNA-Dependent RNA Polymerase from 2019-nCoV, A Major Antiviral drug Target, BioRxiv","author":"Gao","year":"2020"},{"key":"10.1016\/j.cellsig.2020.109721_bb0385","first-page":"65","article-title":"Coronavirus SARS-CoV-2 is the newly emerged zoonotic virus causing pandemic death and economic loss","volume":"9","author":"Ibrahim","year":"2020","journal-title":"EC Pulmonol. Respir. Med."},{"key":"10.1016\/j.cellsig.2020.109721_bb0390","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","article-title":"COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses","volume":"24","author":"Shereen","year":"2020","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.cellsig.2020.109721_bb0395","series-title":"Structural Basis of RNA Cap Modification by SARS-CoV-2 Coronavirus, bioRxiv","author":"Viswanathan","year":"2020"},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0400","first-page":"3","article-title":"Properties of coronavirus and SARS-CoV-2","volume":"42","author":"Malik","year":"2020","journal-title":"Malays. J. Pathol."},{"issue":"7","key":"10.1016\/j.cellsig.2020.109721_bb0405","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.3390\/ijms21072576","article-title":"Lysosomal exocytosis, exosome release and secretory autophagy: the autophagic-and endo-lysosomal systems go extracellular","volume":"21","author":"Buratta","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0410","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov. Ther."},{"issue":"19","key":"10.1016\/j.cellsig.2020.109721_bb0415","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/jama.2020.4742","article-title":"Treating COVID-19\u2014off-label drug use, compassionate use, and randomized clinical trials during pandemics","volume":"323","author":"Kalil","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cellsig.2020.109721_bb0420","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","author":"Sanders","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.cellsig.2020.109721_bb0425","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1148\/radiol.2020200370","article-title":"Time course of lung Changes at chest CT during recovery from coronavirus disease 2019 (COVID-19)","volume":"295","author":"Pan","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.cellsig.2020.109721_bb0430","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.26633\/RPSP.2020.40","article-title":"Clinical trials on drug repositioning for COVID-19 treatment","volume":"44","author":"Rosa","year":"2020","journal-title":"Rev. Panam. Salud Publica"},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0435","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.cellsig.2020.109721_bb0440","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5530\/jyp.2019.11.26","article-title":"Drug repurposing in antiviral research: a current scenario","volume":"11","author":"Mani","year":"2019","journal-title":"J. Young Pharm."},{"issue":"6","key":"10.1016\/j.cellsig.2020.109721_bb0445","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1021\/ml300114c","article-title":"Drug Repurposing and the Medicinal Chemist","volume":"3","author":"Aub\u00e9","year":"2012","journal-title":"CS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.cellsig.2020.109721_bb0450","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJMoa1202657","article-title":"Topical paromomycin with or without gentamicin for cutaneous leishmaniasis","volume":"368","author":"Ben Salah","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cellsig.2020.109721_bb0455","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4269\/ajtmh.2011.10-0285","article-title":"Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis","volume":"84","author":"Tan","year":"2011","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"11","key":"10.1016\/j.cellsig.2020.109721_bb0460","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cellsig.2020.109721_bb0465","doi-asserted-by":"crossref","first-page":"d741","DOI":"10.1136\/bmj.d741","article-title":"Old drugs, new tricks","volume":"342","author":"Shaughnessy","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cellsig.2020.109721_bb0470","article-title":"Virtual screening enabled selection of antiviral agents against Covid-19 disease targeting coronavirus endoribonuclease NendoU: plausible mechanistic interventions in the treatment of new virus strain","author":"Joshi","year":"2020","journal-title":"Chemrxiv"},{"key":"10.1016\/j.cellsig.2020.109721_bb0475","first-page":"1","article-title":"Targeting SARS-Cov-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like Proteinase and 2\u2019-O-RiboseMethyltransferase","author":"Khan","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.cellsig.2020.109721_bb0480","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btaa224","article-title":"Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus","author":"Liu","year":"2020","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0485","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd.2018.92","article-title":"Overcoming the legal and regulatory barriers to drug repurposing","volume":"18","author":"Breckenridge","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.cellsig.2020.109721_bb0495","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.drudis.2018.01.018","article-title":"A bibliometric review of drug repurposing","volume":"23","author":"Baker","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"11-12","key":"10.1016\/j.cellsig.2020.109721_bb0500","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.drudis.2012.12.009","article-title":"Predictive methods in drug repurposing: gold mine or just a bigger haystack?","volume":"18","author":"Cavalla","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.cellsig.2020.109721_bb0505","series-title":"Understanding the cell Biology of SARS-CoV-2 Endocytosis for COVID-19 drug Repurposing: Looking Beyond Chloroquine","author":"Glebov","year":"2020"},{"issue":"2","key":"10.1016\/j.cellsig.2020.109721_bb0510","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/JVI.02062-10","article-title":"A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry","volume":"85","author":"Shulla","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0515","first-page":"1","article-title":"A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin","author":"Hasan","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"11","key":"10.1016\/j.cellsig.2020.109721_bb0520","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1128\/AAC.01043-16","article-title":"Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.cellsig.2020.109721_bb0525","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci. China Life Sci."},{"issue":"9","key":"10.1016\/j.cellsig.2020.109721_bb0530","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.RES.0000187500.24964.7A","article-title":"Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients","volume":"97","author":"Keidar","year":"2005","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.cellsig.2020.109721_bb0535","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/ajh\/hpz146","article-title":"Angiotensin-(1-7): translational avenues in cardiovascular control","volume":"32","author":"Medina","year":"2019","journal-title":"Am. J. Hypertens."},{"issue":"4","key":"10.1016\/j.cellsig.2020.109721_bb0540","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.cellsig.2020.109721_bb0545","doi-asserted-by":"crossref","first-page":"H137","DOI":"10.1152\/ajpheart.00618.2015","article-title":"Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?","volume":"310","author":"Chappell","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0550","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.cellsig.2020.109721_bb0555","doi-asserted-by":"crossref","first-page":"72","DOI":"10.12688\/f1000research.22211.2","article-title":"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China","volume":"9","author":"Kruse","year":"2020","journal-title":"F1000Res"},{"issue":"22","key":"10.1016\/j.cellsig.2020.109721_bb0560","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1016\/j.febslet.2006.08.083","article-title":"Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues","volume":"580","author":"Wehkamp","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.cellsig.2020.109721_bb0565","article-title":"Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China","author":"Wang","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cellsig.2020.109721_bb0570","article-title":"Does the pathogenesis of SAR-CoV-2 virus decrease at high-altitude?","volume":"103443","author":"Arias-Reyes","year":"2020","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0575","doi-asserted-by":"crossref","first-page":"112470","DOI":"10.1016\/j.jep.2019.112470","article-title":"Tsantan Sumtang attenuated chronic hypoxia-induced right ventricular structure remodeling and fibrosis by equilibrating local ACE-AngII-AT1R\/ACE2-Ang1-7-Mas axis in rat","volume":"250","author":"Dang","year":"2020","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0580","doi-asserted-by":"crossref","first-page":"102433","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.cellsig.2020.109721_bb0585","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/ajh\/hpu197","article-title":"Neuroprotective effects of angiotensin receptor blockers","volume":"28","author":"Villapol","year":"2015","journal-title":"Am. J. Hypertens."},{"issue":"2","key":"10.1016\/j.cellsig.2020.109721_bb0590","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/1874467211205020219","article-title":"EDITORIAL [Hot Topic-II: PPAR ligands and cardiovascular disorders: friend or Foe (Guest Editors: Pitchai Balakumar and Gowraganahalli Jagadeesh)]","volume":"5","author":"Balakumar","year":"2012","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0595","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","author":"Guo","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0600","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.0950","article-title":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China","author":"Shi","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0605","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2020-0198","article-title":"Laboratory abnormalities in patients with COVID-2019 infection","author":"Lippi","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"issue":"4","key":"10.1016\/j.cellsig.2020.109721_bb0610","article-title":"Corona virus disease 2019 (COVID-19) presenting as acute ST elevation myocardial infarction","volume":"12","author":"Siddamreddy","year":"2020","journal-title":"Cureus"},{"issue":"20","key":"10.1016\/j.cellsig.2020.109721_bb0615","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0620","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ajh\/hpu086","article-title":"Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker","volume":"28","author":"Furuhashi","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.cellsig.2020.109721_bb0625","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of Renin-angiotensin system inhibitors with severity or risk of death in Patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) Infection in Wuhan, China","author":"Li","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0630","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"12","key":"10.1016\/j.cellsig.2020.109721_bb0635","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1258\/ebm.2012.012212","article-title":"Cross-talk between inflammation and angiotensin II: studies based on direct transfection of cardiomyocytes with AT1R and AT2R cDNA","volume":"237","author":"Xianwei","year":"2012","journal-title":"Exp. Biol. Med."},{"issue":"4","key":"10.1016\/j.cellsig.2020.109721_bb0640","doi-asserted-by":"crossref","first-page":"H1377","DOI":"10.1152\/ajpheart.00331.2008","article-title":"Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis","volume":"295","author":"Lovren","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.cellsig.2020.109721_bb0645","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bcp.2014.11.013","article-title":"Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications","volume":"93","author":"Tikoo","year":"2015","journal-title":"Biochem. Pharmacol."},{"issue":"18","key":"10.1016\/j.cellsig.2020.109721_bb0650","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J."},{"key":"10.1016\/j.cellsig.2020.109721_bb0655","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0660","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13063-017-2427-0","article-title":"Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-\u03b21b (MIRACLE trial): study protocol for a randomized controlled trial","volume":"19","author":"Arabi","year":"2018","journal-title":"Trials"},{"issue":"6489","key":"10.1016\/j.cellsig.2020.109721_bb0665","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2020.109721_bb0670","first-page":"1","article-title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur","author":"Jin","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0675","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","author":"Yin","year":"2020","journal-title":"Science"},{"issue":"10236","key":"10.1016\/j.cellsig.2020.109721_bb0680","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cellsig.2020.109721_bb0685","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fpubh.2020.00189","article-title":"Severe COVID-19: a review of recent progress with a look toward the future","volume":"8","author":"Xie","year":"2020","journal-title":"Front. Public Health"},{"key":"10.1016\/j.cellsig.2020.109721_bb0690","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvaa106","article-title":"COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options","author":"Guzik","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.cellsig.2020.109721_bb0695","article-title":"Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia","author":"McGonagle","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0700","first-page":"1","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","author":"Ruan","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.cellsig.2020.109721_bb0705","series-title":"Chinese Clinical Guidance For COVID-19 Pneumonia Diagnosis and Treatment. 4 March 2020","author":"C.N.H. Commission","year":"2020"},{"key":"10.1016\/j.cellsig.2020.109721_bb0710","article-title":"Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19","volume":"102463","author":"Li","year":"2020","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0715","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/microorganisms8010085","article-title":"The use of antimalarial drugs against viral infection","volume":"8","author":"D\u2019Alessandro","year":"2020","journal-title":"Microorganisms"},{"issue":"3","key":"10.1016\/j.cellsig.2020.109721_bb0720","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0725","article-title":"Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus","author":"Zhou","year":"2020","journal-title":"BioRxiv"},{"issue":"4","key":"10.1016\/j.cellsig.2020.109721_bb0730","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/CS20110340","article-title":"IL-6\/IL-6 receptor system and its role in physiological and pathological conditions","volume":"122","author":"Mihara","year":"2012","journal-title":"Clin. Sci. (Lond.)"},{"issue":"3","key":"10.1016\/j.cellsig.2020.109721_bb0735","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000505099","article-title":"Interleukin-6: A Masterplayer in the Cytokine Network","volume":"98","author":"Uciechowski","year":"2020","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.cellsig.2020.109721_bb0740","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/annrheumdis-2020-217442","article-title":"COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD","volume":"79","author":"Mihai","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.cellsig.2020.109721_bb0745","doi-asserted-by":"crossref","first-page":"175","DOI":"10.55563\/clinexprheumatol\/r3k9l6","article-title":"COVID-19: the new challenge for rheumatologists","volume":"38","author":"Ferro","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0750","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"Biodrugs"},{"issue":"Supplement_1","key":"10.1016\/j.cellsig.2020.109721_bb0755","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. new players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"issue":"10223","key":"10.1016\/j.cellsig.2020.109721_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.cellsig.2020.109721_bb0765","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: re-analysis of a prior Phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.cellsig.2020.109721_bb0770","article-title":"The Greek study in the effects of colchicine in Covid-19 complications prevention (GRECCO-19 study): Rationale and study design","author":"Deftereos","year":"2020","journal-title":"Hell. J. Cardiol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0775","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2020.109721_bb0780","first-page":"1","article-title":"The SARS-CoV-2 vaccine pipeline: an overview","author":"Chen","year":"2020","journal-title":"Curr. Trop. Med. Rep."},{"key":"10.1016\/j.cellsig.2020.109721_bb0785","author":"T.S.A. Board"},{"issue":"4","key":"10.1016\/j.cellsig.2020.109721_bb0790","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.cellsig.2020.109721_bb0795","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0800","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-52768-7","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2020.109721_bb0805","series-title":"Regulation of Interferon Production as a Potential Strategy for COVID-19 Treatment","author":"Deng","year":"2020"},{"key":"10.1016\/j.cellsig.2020.109721_bb0810","doi-asserted-by":"crossref","DOI":"10.1089\/nat.2020.0868","article-title":"Oligonucleotides and the COVID-19 pandemic: a perspective","author":"Rossi","year":"2020","journal-title":"Nucl. Acid Ther."},{"key":"10.1016\/j.cellsig.2020.109721_bb0815","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25829","article-title":"Hematological findings and complications of COVID-19","author":"Terpos","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0820","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","volume":"102452","author":"Liu","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cellsig.2020.109721_bb0825","series-title":"A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals, bioRxiv","author":"Riva","year":"2020"},{"issue":"2","key":"10.1016\/j.cellsig.2020.109721_bb0830","first-page":"1","article-title":"19: Camostat and The Role of Serine Protease Entry Inhibitor TMPRSS2","volume":"2","author":"Bittmann","year":"2020","journal-title":"J. Regen Biol. Med."},{"key":"10.1016\/j.cellsig.2020.109721_bb0835","article-title":"The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells","author":"Hoffmann","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.cellsig.2020.109721_bb0840","doi-asserted-by":"crossref","DOI":"10.26633\/RPSP.2020.40","article-title":"Clinical trials on drug repositioning for COVID-19 treatment","volume":"44","author":"Rosa","year":"2020","journal-title":"Rev. Panam. Salud Publica"},{"issue":"3","key":"10.1016\/j.cellsig.2020.109721_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"7","key":"10.1016\/j.cellsig.2020.109721_bb0850","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016219","volume":"9","author":"Guo","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"12","key":"10.1016\/j.cellsig.2020.109721_bb0855","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/ajh\/hpz146","article-title":"Angiotensin-(1-7): Translational Avenues in Cardiovascular Control","volume":"32","author":"Medina","year":"2019","journal-title":"Am. J. Hypertens."},{"issue":"6","key":"10.1016\/j.cellsig.2020.109721_bb0860","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.kint.2020.04.009","article-title":"Blockade of SARS-CoV-2 infection by recombinant soluble ACE2","volume":"97","author":"Alhenc-Gelas","year":"2020","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.cellsig.2020.109721_bb0865","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1042\/CS20200163","article-title":"Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?","volume":"134","author":"Batlle","year":"2020","journal-title":"Clin. Sci."},{"key":"10.1016\/j.cellsig.2020.109721_bb0870","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.peptides.2014.07.002","article-title":"Angiotensin 1\u20137: A peptide for preventing and treating metabolic syndrome","volume":"59","author":"Santos","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.cellsig.2020.109721_bb0875","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.120.047297","article-title":"Substituting angiotensin-(1-7) to prevent lung damage in SARSCoV2 infection?","author":"Peir\u00f3","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cellsig.2020.109721_bb0880","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cellsig.2020.109721_bb0885","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1097\/HJH.0000000000002469","article-title":"Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus","volume":"38","author":"Verdecchia","year":"2020","journal-title":"J. Hypertens."},{"issue":"1512","key":"10.1016\/j.cellsig.2020.109721_bb0890","first-page":"85","article-title":"A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019)","volume":"133","author":"Talreja","year":"2020","journal-title":"The New Zealand Med. J."},{"key":"10.1016\/j.cellsig.2020.109721_bb0895","first-page":"1","article-title":"Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors\u2014lessons from available evidence and insights into COVID-19","author":"Kai","year":"2020","journal-title":"Hypertens. Res."},{"issue":"5","key":"10.1016\/j.cellsig.2020.109721_bb0900","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30158-2","article-title":"Antihypertensive drugs and risk of COVID-19?","volume":"8","author":"Brown","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.cellsig.2020.109721_bb0905","series-title":"Inhibition of Viral Macrodomain of COVID-19 and Human TRPM2 by Losartan","author":"Mahnam","year":"2020"},{"issue":"6","key":"10.1016\/j.cellsig.2020.109721_bb0910","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1017\/ice.2020.80","article-title":"A potential protective role of losartan against coronavirus-induced lung damage","volume":"41","author":"Zeinalian","year":"2020","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"10.1016\/j.cellsig.2020.109721_bb0915","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.21679","article-title":"Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19","author":"Rothlin","year":"2020","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.cellsig.2020.109721_bb0920","doi-asserted-by":"crossref","first-page":"104803","DOI":"10.1016\/j.phrs.2020.104803","article-title":"Statins in coronavirus outbreak: it\u2019s time for experimental and clinical studies","volume":"156","author":"Bifulco","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.cellsig.2020.109721_bb0925","doi-asserted-by":"crossref","first-page":"485","DOI":"10.5114\/aoms.2020.94503","article-title":"Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic","volume":"16","author":"Katsiki","year":"2020","journal-title":"Arch. Med. Sci."},{"issue":"4","key":"10.1016\/j.cellsig.2020.109721_bb0930","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ehjcvp\/pvaa042","article-title":"Statin therapy in COVID-19 infection","volume":"6","author":"Castiglione","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb0935","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.cellsig.2020.109721_bb0940","first-page":"22","article-title":"In vitro testing of hydroxychloroquine and azithromycin on SARS-CoV-2 shows 1 synergistic effect 2","volume":"21","author":"Andreania","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.cellsig.2020.109721_bb0945","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkaa190","article-title":"Lopinavir\/ritonavir in COVID-19 patients: maybe yes, but at what dose?","author":"Baldelli","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cellsig.2020.109721_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","author":"Hung","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cellsig.2020.109721_bb0955","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1128\/AAC.00055-12","article-title":"Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing","volume":"56","author":"Davis","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cellsig.2020.109721_bb0960","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.1844","article-title":"Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection","volume":"108","author":"Du","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cellsig.2020.109721_bb0965","doi-asserted-by":"crossref","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.cellsig.2020.109721_bb0970","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe COVID-19","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2020.109721_bb0975","article-title":"HBV replication inhibitors","volume":"179","author":"Rouviere","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.cellsig.2020.109721_bb0980","series-title":"Triphosphates of the Two Components in DESCOVY and TRUVADA are Inhibitors of the SARS-CoV-2 Polymerase, bioRxiv","author":"Jockusch","year":"2020"},{"key":"10.1016\/j.cellsig.2020.109721_bb0985","series-title":"The Inhaled Corticosteroid Ciclesonide blocks Coronavirus RNA Replication by Targeting Viral NSP15, bioRxiv","author":"Matsuyama","year":"2020"},{"issue":"6","key":"10.1016\/j.cellsig.2020.109721_bb0990","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.mayocp.2020.04.007","article-title":"A Case of Coronavirus Disease 2019 Treated With Ciclesonide","volume":"95","author":"Nakajima","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.cellsig.2020.109721_bb0995","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3389\/fphar.2020.00625","article-title":"Small molecule inhibitors of CRM1","volume":"11","author":"Ferreira","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cellsig.2020.109721_bb1000","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.cellsig.2020.109721_bb1005","first-page":"1","article-title":"Rheumatologists perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets","author":"Misra","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cellsig.2020.109721_bb1010","article-title":"Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support","author":"Gritti","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.cellsig.2020.109721_bb1015","series-title":"Interleukin-6 Blockade for Severe COVID-19","author":"Roumier","year":"2020"},{"issue":"4","key":"10.1016\/j.cellsig.2020.109721_bb1020","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cellsig.2020.109721_bb1025","article-title":"Immunoregulation with mTOR inhibitors to prevent COVID\u201019 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines","author":"Zheng","year":"2020","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb1030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13054-020-02851-4","article-title":"A new clinical trial to test high-dose vitamin C in patients with COVID-19","volume":"24","author":"Carr","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.cellsig.2020.109721_bb1035","doi-asserted-by":"crossref","first-page":"100190","DOI":"10.1016\/j.phanu.2020.100190","article-title":"Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome","volume":"12","author":"Boretti","year":"2020","journal-title":"PharmaNutrition."},{"key":"10.1016\/j.cellsig.2020.109721_bb1040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/DDDT.S195294","article-title":"Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy","volume":"13","author":"Cohen","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"issue":"1","key":"10.1016\/j.cellsig.2020.109721_bb1045","first-page":"1","article-title":"Thalidomide against coronavirus disease 2019 (COVID-19): A medicine with a thousand faces","volume":"19","author":"Dastan","year":"2020","journal-title":"Iran. J. Pharm. Res."},{"key":"10.1016\/j.cellsig.2020.109721_bb1050","article-title":"Home NO therapy for COVID-19","volume":"ja","author":"Alvarez","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cellsig.2020.109721_bb1055","doi-asserted-by":"crossref","first-page":"041","DOI":"10.29328\/journal.ijcv.1001014","article-title":"COVID-19: Targeting the cytokine storm via cholinergic anti-inflammatory (Pyridostigmine)","volume":"4","author":"Osman","year":"2020","journal-title":"Int. J. Clin. Virol."},{"key":"10.1016\/j.cellsig.2020.109721_bb1060","article-title":"Management of patients with generalised myasthenia gravis and COVID-19: four case reports","author":"Annemarie","year":"2020","journal-title":"J. Neurol. Neurosurgery Psychiatry"},{"key":"10.1016\/j.cellsig.2020.109721_bb1065","article-title":"BTK inhibitors in cancer patients with COVID19:\" The winner will be the one who controls that chaos\"(Napoleon Bonaparte)","author":"Chong","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1111","key":"10.1016\/j.cellsig.2020.109721_bb1070","first-page":"13853","article-title":"Could CGRP antagonists be helpful in the fight against COVID-19?","volume":"10","author":"Robertson","year":"2020","journal-title":"Headache J. Head Face Pain"},{"issue":"6","key":"10.1016\/j.cellsig.2020.109721_bb1075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellsig.2020.109721_bb1080","series-title":"Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning","author":"Farag","year":"2020"},{"key":"10.1016\/j.cellsig.2020.109721_bb1085","doi-asserted-by":"crossref","first-page":"138605","DOI":"10.1016\/j.scitotenv.2020.138605","article-title":"Assessing nitrogen dioxide (NO2) levels as a contributing factor to the coronavirus (COVID-19) fatality rate","volume":"726","author":"Ogen","year":"2020","journal-title":"Sci. Total Environ."},{"issue":"6","key":"10.1016\/j.cellsig.2020.109721_bb1090","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12630-020-01630-7","article-title":"Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients","volume":"67","author":"Chen","year":"2020","journal-title":"Can. J. Anaesth."},{"issue":"5","key":"10.1016\/j.cellsig.2020.109721_bb1095","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00415-020-09822-3","article-title":"Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19\/SARS-CoV-2","volume":"267","author":"Willis","year":"2020","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.cellsig.2020.109721_bb1100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tips.2020.03.006","article-title":"Ongoing clinical trials for the management of the COVID-19 pandemic","volume":"41","author":"Lythgoe","year":"2020","journal-title":"Trends Pharmacol. Sci."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656820301984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656820301984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:57:45Z","timestamp":1760266665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656820301984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":220,"alternative-id":["S0898656820301984"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2020.109721","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2020.109721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109721"}}